BRCA2 and cancer: We were curious to see if RPA:RAD52 PPI inhibitors would show synthetic lethality in HR-deficient cancer cell lines, so we examined the cytotoxicity of quinacrine, mitoxantrone, and doxorubicin in cells with impaired BRCA1 or BRCA2 function.